The sNDA is supported by data from the phase 3 ENERGIZE and ENERGIZE-T studies, which evaluated mitapivat vs placebo in patients with NTD and TD alpha- or beta-thalassemia, respectively.

HealthDay News — Eight in 10 infants received respiratory syncytial virus (RSV) protection during the 2023 to 2024 season, according to a research letter published online January 8 in JAMA Network ...

Multidisciplinary collaborative approach to care is required for patients with hematological malignancies in pregnancy.

Morning-type pattern significantly linked to lower risks for all-cause and cardiovascular disease-specific mortality compared with non-coffee drinking ...

Meaningful reduction in symptoms seen for some taking an extended course outside of the context of an acute infection ...

Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.

HealthDay News — Doxycycline postexposure prophylaxis (doxyPEP) initiation is associated with decreases in sexually transmitted infections (STIs), according to a study published online January 6 in ...

Topline data were announced from the AUDACITY trial evaluating the Allurion Gastric Balloon, a swallowable, procedureless intragastric balloon, in adults with obesity.

Adverse events were frequent, and most were gastrointestinal-related, including nausea, vomiting, diarrhea, constipation.

Denosumab has greater preventive effect on fractures, but increased risk for MACE compared with oral bisphosphonates.

Posdinemab works by targeting and neutralizing Alzheimer disease-specific phosphorylated tau, preventing its spread to other neurons.

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.